The influence of stroke risk factors and comorbidities on assessment of stroke therapies in humans and animals

International Journal of Stroke

Volumn 7, Issue 5, 2012, Pages 386-397

  Ankolekar, Sandeep ^a   Rewell, Sarah ^b   Howells, David W ^b   Bath, Philip M W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Acute stroke; Animal models; Diabetes; Hypertension; Risk factors; Stroke therapies

Indexed keywords

AGE; ALCOHOL CONSUMPTION; COMORBIDITY; DIABETES MELLITUS; ETHNICITY; FAMILY HISTORY; GENDER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LOW BIRTH WEIGHT; NONHUMAN; OBESITY; PRIORITY JOURNAL; RACE; REVIEW; RISK FACTOR; SEDENTARY LIFESTYLE; SMOKING; STROKE;

AGE FACTORS; ALCOHOL DRINKING; ANIMALS; ATRIAL FIBRILLATION; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOGS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MICE; RABBITS; RATS; RATS, INBRED SHR; RATS, WISTAR; RISK FACTORS; SEX FACTORS; SMOKING; STROKE;

EID: 84862691399     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00802.x     Document Type: Review

References (235)

1. Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 2004; 19:151-167.
2. Phan TG, Wright PM, Markus R, Howells DW, Davis SM, Donnan GA. Salvaging the ischaemic penumbra: more than just reperfusion? Clin Exp Pharmacol Physiol 2002; 29:1-10.
3. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010; 17:197-218.
4. Verhaegen MJ, Todd MM, Warner DS. A comparison of cerebral ischemic flow thresholds during halothane/N2O and isoflurane/N2O anesthesia in rats. Anesthesiology 1992; 76:743-754.
5. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981; 12:723-725.
6. Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997; 28:708-710.
7. Dominguez C, Delgado P, Vilches A etal. Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke 2010; 41:653-660.
8. Nilupul Perera M, Ma HK, Arakawa S etal. Inflammation following stroke. J Clin Neurosci 2006; 13:1-8.
9. Prass K, Braun JS, Dirnagl U, Meisel C, Meisel A. Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 2006; 37:2607-2612.
10. Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, Macleod MR. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab 2010; 2:1905-1913.
11. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59:467-477.
12. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30:2752-2758.
13. Fisher M, Feuerstein GZ, Howells DW etal. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 6:2244-2250.
14. O'Donnell MJ, Xavier D, Liu L etal. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376:112-123.
15. Goldstein LB, Bushnell CD, Adams RJ etal. Guidelines for the primary prevention of stroke. Stroke 2011; 42:517-584.
16. Nakayama H, Jorgensen H, Raaschou H, Olsen T. The influence of age on stroke outcome. The Copenhagen Stroke Study. Stroke 1994; 25:808-813.
17. Marini C, Baldassarre M, Russo T etal. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004; 62:77-81.
18. Mishra NK, Ahmed N, Andersen G etal. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046
19. Kerenyi L, Kardos L, Szász J etal. Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison. Eur J Neurol 2006; 13:1251-1255.
20. Yamori Y, Horie R. Developmental course of hypertension and regional cerebral blood flow in stroke-prone spontaneously hypertensive rats. Stroke 1977; 8:456-461.
21. Song SW, Liu AJ, Bai C etal. Blood pressure reduction combining baroreflex restoration for stroke prevention in hypertension in rats. Front Pharmacol 2010; 1:6.
22. Zhou Y, Yu F, Ene AR, Catanzaro DF. Telmisartan ramipril combination therapy reduces strokes and improves cardiac and renal protection in stroke prone spontaneously hypertensive rats. J Am Soc Hypertens 2007; 1:423-432.
23. Wang RY, Wang PS, Yang YR. Effect of age in rats following middle cerebral artery occlusion. Gerontology 2003; 49:27-32.
24. Chen Y, Sun FY. Age-related decrease of striatal neurogenesis is associated with apoptosis of neural precursors and newborn neurons in rat brain after ischemia. Brain Res 2007; 1166:9-19.
25. DiNapoli VA, Huber JD, Houser K, Li X, Rosen CL. Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats. Neurobiol Aging 2008; 29:753-764.
26. Popa-Wagner A, Badan I, Walker L, Groppa S, Patrana N, Kessler C. Accelerated infarct development, cytogenesis and apoptosis following transient cerebral ischemia in aged rats. Acta Neuropathol 2007; 113:277-293.
27. Tan Z, Li X, Kelly KA, Rosen CL, Huber JD. Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion. Brain Res 2009; 1281:84-90.
28. Popa-Wagner A, Carmichael ST, Kokaia Z, Kessler C, Walker LC. The response of the aged brain to stroke: too much, too soon? Curr Neurovasc Res 2007; 4:216-227.
29. Desbordes P, Cohadon F. Brain water and aging. J Gerontol 1987; 42:655-659.
30. Wenk GL, Walker LC, Price DL, Cork LC. Loss of NMDA, but not GABA-A, binding in the brains of aged rats and monkeys. Neurobiol Aging 1991; 12:93-98.
31. DiNapoli VA, Benkovic SA, Li X etal. Age exaggerates proinflammatory cytokine signaling and truncates signal transducers and activators of transcription 3 signaling following ischemic stroke in the rat. Neuroscience 2010; 170:633-644.
32. Cakman I, Rohwer J, Schutz RM, Kirchner H, Rink L. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev 1996; 87:197-209.
33. Merrett DL, Kirkland SW, Metz GA. Synergistic effects of age and stress in a rodent model of stroke. Behav Brain Res 2010; 214:55-59.
34. Li S, Overman JJ, Katsman D etal. An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci 2010; 13:1496-1504.
35. Won SJ, Xie L, Kim SH etal. Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke. Brain Res 2006; 1123:237-244.
36. Yager JY, Wright S, Armstrong EA, Jahraus CM, Saucier DM. The influence of aging on recovery following ischemic brain damage. Behav Brain Res 2006; 173:171-180.
37. Roussel BD, Macrez R, Jullienne A etal. Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 2009; 132 (Pt 8): 2219-2230.
38. Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke 2009; 40:1082-1090.
39. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 years follow up of the Framingham population. Am Heart J 1986; 111:383-390.
40. Forster A, Gass A, Kern R etal. Gender differences in acute ischemic stroke: etiology, stroke patterns and response to thrombolysis. Stroke 2009; 40:2428-2432.
41. Giralt D, Domingues-Montanari S, Mendioroz M etal. The gender gap in stroke: a meta-analysis. Acta Neurol Scand 2011; 125:83-90.
42. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. J Am Med Assoc 2006; 295:306-313.
43. Kent DM, Buchan AM, Hill MD. The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification. Neurology 2008; 71:1080-1083.
44. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101:938-942.
45. Fang MC, Singer DE, Chang Y etal. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112:1687-1691.
46. Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta analysis. Eur Heart J 2008; 29:2031-2041.
47. Yager JY, Wright S, Armstrong EA, Jahraus CM, Saucier DM. A new model for determining the influence of age and sex on functional recovery following hypoxic-ischemic brain damage. Dev Neurosci 2005; 27:112-120.
48. Liu F, Yuan R, Benashski SE, McCullough LD. Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab 2009; 29:792-802.
49. Brait VH, Jackman KA, Walduck AK etal. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010; 30:1306-1317.
50. Cheng J, Hu WD, Toung TJ etal. Age-dependent effects of testosterone in experimental stroke. J Cereb Blood Flow Metab 2009; 29:486-494.
51. Gibson CL, Gray LJ, Murphy SP, Bath PMB. Estrogen and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 2006; 26:1103-1113.
52. Gibson CL, Gray LJ, Bath PMW, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131:318-328.
53. Toung TJ, Chen T-Y, Littleton-Kearney MT, Hurn PD, Murphy SJ. Effects of combined estrogen and progesterone on brain infarction in reproductively senescent female rats. J Cereb Blood Flow Metab 2004; 24:1160-1166.
54. Strom JO, Theodorsson A, Theodorsson E. Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis. J Cereb Blood Flow Metab 2009; 29:1359-1372.
55. Wang X, Desai K, Juurlink BHJ, de Champlain J, Wu L. Gender-related differences in advanced glycation endproducts, oxidative stress markers and nitric oxide synthases in rats. Kidney Int 2006; 69:281-287.
56. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 2005; 25:502-512.
57. Zeynalov E, Nemoto M, Hurn PD, Koehler RC, Bhardwaj A. Neuroprotective effect of selective kappa opioid receptor agonist is gender specific and linked to reduced neuronal nitric oxide. J Cereb Blood Flow Metab 2006; 26:414-420.
58. Li J, McCullough LD. Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab 2009; 29:670-674.
59. Mathers C, Boerma T, Ma Fat D. Part 2: Causes of Death, The Global Burden of Disease, 2004 update. World Health Organization, 2008.
60. Roger VL, Go AS, Lloyd-Jones DM etal. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123:e18-e209.
61. Markus HS, Khan U, Birns J etal. Differences in stroke subtypes between black and white patients with stroke. Circulation 2007; 116:2157-2164.
62. Schwamm LH, Reeves MJ, Pan W etal. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010; 121:1492-1501.
63. Halm EA, Tuhrim S, Wang JJ etal. Racial and ethnic disparities in outcomes and appropriateness of carotid endarterectomy: impact of patient and provider factors. Stroke 2009; 40:2493-2501.
64. Xian Y, Holloway RG, Noyes K, Shah MN, Friedman B. Racial differences in mortality among patients with acute ischemic stroke: an observational study. Ann Intern Med 2011; 154:152-159.
65. Rosamond WD, Folsom AR, Chambless LE etal. Stroke Incidence and Survival Among Middle-Aged Adults : 9-Year Follow-Up of the Atherosclerosis Risk in Communities (ARIC) Cohort. Stroke 1999; 30:736-743.
66. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002; 325:1271.
67. Gunarathne A, Patel JV, Potluri R, Gill PS, Hughes EA, Lip GY. Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997-2005). J Hum Hypertens 2008; 22:18-23.
68. Andersen KK, Andersen ZJ, Olsen TS. Predictors of early and late case-fatality in a nationwide danish study of 26 818 patients with first-ever ischemic stroke. Stroke 2011; 42:2806-2812.
69. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92:17-40.
70. Olsen TS, Christensen RH, Kammersgaard LP, Andersen KK. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 2007; 38:2646-2651.
71. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better outcome after stroke with higher serum cholesterol levels. Neurology 2000; 54:1944-1949.
72. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342:d671
73. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PA; for the IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315-1320.
74. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients. Stroke 2001; 32:2426-2432.
75. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GYH. Ischemic stroke in South Asians. Stroke 2009; 40:e415-423.
76. Burke TA, Venketasubramanian RN. The epidemiology of stroke in the East Asian region: a literature-based review. Int J Stroke 2006; 1:208-215.
77. Nguyen-Huynh MN, Johnston SC. Regional variation in hospitalization for stroke among Asians/Pacific Islanders in the United States: a nationwide retrospective cohort study. BMC Neurol 2005; 5:21.
78. Benamer HT, Grosset D. Stroke in Arab countries: a systematic literature review. J Neurol Sci 2009; 284:18-23.
79. Howard G, Prineas R, Moy C etal. Racial and geographic differences in awareness, treatment, and control of hypertension: the REasons for Geographic And Racial Differences in Stroke study. Stroke 2006; 37:1171-1178.
80. Banerjee D, Wong EC, Shin J, Fortmann SP, Palaniappan L. Racial and ethnic variation in lipoprotein (a) levels among Asian Indian and Chinese patients. J Lipids 2011; 2011:291954.
81. Joutel A, Corpechot C, Ducros A etal. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383:707-710.
82. Chabriat H, Vahedi K, Iba-Zizen MT etal. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995; 346:934-939.
83. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 2005; 36:1053-1058.
84. Ruchoux MM, Domenga V, Brulin P etal. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol 2003; 162:329-342.
85. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18, 000 cases and 58, 000 controls. Arch Neurol 2004; 61:1652-1661.
86. Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32, 500 individuals. PLoS Med 2007; 4:e131.
87. Hermans MP, Gala JL, Buysschaert M. The MTHFR CT polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes. Diabet Med 2006; 23:529-536.
88. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
89. Arboix A, Roig H, Rossich R, Martinez EM, Garcia-Eroles L. Differences between hypertensive and non-hypertensive ischemic stroke. Eur J Neurol 2004; 11:687-692.
90. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [see comment] [erratum appears in Lancet 2003 Mar 22;361(9362):1060]. Lancet 2002; 360:1903-1913.
91. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
92. Whisnant JP. Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Neurology 1996; 46:301-307.
93. Rodgers A, MacMahon S, Gamble G etal. Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 1996; 313:147.
94. Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B etal. Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. Arch Intern Med 2004; 164:1761-1768.
95. Meyer JS, Shimazu K, Fukuuchi Y etal. Impaired neurogenic cerebrovascular control and dysautoregulation after stroke. Stroke 1973; 4:169-186.
96. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004; 43:18-24.
97. Geeganage C, Bath PMW. Relationship between therapeutic changes in blood pressure and outcomes in acute stroke. A metaregression. Hypertension 2009; 54:775-781.
98. Sandset EC, Bath PM, Boysen G etal. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741-750.
99. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27:282-293.
100. Fredriksson K, Kalimo H, Nordborg C, Johansson BB, Olsson Y. Nerve cell injury in the brain of stroke-prone spontaneously hypertensive rats. Acta Neuropathol 1988; 76:227-237.
101. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39:77-88.
102. Fukushima M. Histometric and histochemical studies of the hypothalamo-hypophyseal neurosecretory system of spontaneously hypertensive rats and rats with experimental hypertension. Jpn Circ J 1968; 32:485-516.
103. Nelson DO, Boulant JA. Altered CNS neuroanatomical organization of spontaneously hypertensive (SHR) rats. Brain Res 1981; 226:119-130.
104. Tajima A, Hans FJ, Livingstone D etal. Smaller local brain volumes and cerebral atrophy in spontaneously hypertensive rats. Hypertension 1993; 21:105-111.
105. Bendel P, Eilam R. Quantitation of ventricular size in normal and spontaneously hypertensive rats by magnetic resonance imaging. Brain Res 1992; 574:224-228.
106. Mangiarua EI, Lee RM. Morphometric study of cerebral arteries from spontaneously hypertensive and stroke-prone spontaneously hypertensive rats. J Hypertens 1992; 10:1183-1190.
107. Liu Y, Liu T, McCarron RM etal. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996; 270 (6 Pt 2): H2125-2131.
108. Yamori Y, Horie R, Handa H, Sato M, Fukase M. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 1976; 7:46-53.
109. Guerrini U, Sironi L, Tremoli E etal. New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 2002; 33:825-830.
110. Jacewicz M. The hypertensive rat and predisposition to cerebral infarction. Hypertension 1992; 19:47-48.
111. Coyle P, Jokelainen PT. Dorsal cerebral arterial collaterals of the rat. Anat Rec 1982; 203:397-404.
112. Nabika T, Cui Z, Masuda J. The stroke-prone spontaneously hypertensive rat: how good is it as a model for cerebrovascular diseases? Cell Mol Neurobiol 2004; 24:639-646.
113. Coyle P, Heistad DD. Blood flow through cerebral collateral vessels in hypertensive and normotensive rats. Hypertension 1986; 8 (6 Pt 2): II67-71.
114. Baumbach GL, Heistad DD, Siems JE. Effect of sympathetic nerves on composition and distensibility of cerebral arterioles in rats. J Physiol 1989; 416:123-140.
115. Yang ST, Faraci FM, Heistad DD. Effects of cilazapril on cerebral vasodilatation in hypertensive rats. Hypertension 1993; 22:150-155.
116. Kidd GA, Dobrucki LW, Brovkovych V, Bohr DF, Malinski T. Nitric oxide deficiency contributes to large cerebral infarct size. Hypertension 2000; 35:1111-1118.
117. Barone FC, Price WJ, White RF, Willette RN, Feuerstein GZ. Genetic hypertension and increased susceptibility to cerebral ischemia. Neurosci Biobehav Rev 1992; 16:219-233.
118. Spratt NJ, Fernandez J, Chen M etal. Modification of the method of thread manufacture improves stroke induction rate and reduces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. J Neurosci Methods 2006; 155:285-290.
119. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke 1989; 20:1627-1642.
120. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 1988; 8:474-485.
121. Gratton JA, Sauter A, Rudin M etal. Susceptibility to cerebral infarction in the stroke-prone spontaneously hypertensive rat is inherited as a dominant trait. Stroke 1998; 29:690-694.
122. Amiri F, Garcia R. Renal angiotensin II receptor regulation in two-kidney, one clip hypertensive rats: effect of ACE inhibition. Hypertension 1997; 30 (3 Pt 1): 337-344.
123. Fujishima M, Onoyama K, Oniki H, Ogata J, Omae T. Effects of acute hypertension on brain metabolism in normotensive, renovascular hypertensive and spontaneously hypertensive rats. Stroke 1978; 9:349-353.
124. Zeng J, Zhang Y, Mo J, Su Z, Huang R. Two-kidney, two clip renovascular hypertensive rats can be used as stroke-prone rats. Stroke 1998; 29:1708-1713; discussion 1713-14.
125. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol 1984; 62:178-184.
126. Nag S, Kilty DW. Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Stroke 1997; 28:1028-1034.
127. Del Bigio MR, Yan HJ, Kozlowski P, Sutherland GR, Peeling J. Serial magnetic resonance imaging of rat brain after induction of renal hypertension. Stroke 1999; 30:2440-2447.
128. Zhao Z, Yu J, Liao S etal. Delayed decompressive craniectomy improves the long-term outcomes in hypertensive rats with space-occupying cerebral infarction. Neurocrit Care 2007; 7:263-269.
129. Wakisaka Y, Chu Y, Miller JD, Rosenberg GA, Heistad DD. Spontaneous intracerebral hemorrhage during acute and chronic hypertension in mice. J Cereb Blood Flow Metab 2010; 30:56-69.
130. Shibota M, Nagaoka A, Shino A, Fujita T. Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. Am J Physiol 1979; 236:H409-416.
131. Lee JM, Zhai G, Liu Q etal. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke 2007; 38:3289-3291.
132. Churchill PC, Churchill MC, Griffin KA etal. Increased genetic susceptibility to renal damage in the stroke-prone spontaneously hypertensive rat. Kidney Int 2002; 61:1794-1800.
133. Meneely GR, Ball CO. Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med 1958; 25:713-725.
134. Payne GW, Smeda JS. Cerebrovascular alterations in pressure and protein kinase C-mediated constriction in Dahl salt-sensitive rats. J Hypertens 2002; 20:1355-1363.
135. Rapp JP, Dene H. Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. Hypertension 1985; 7 (3 Pt 1): 340-349.
136. Bright R, Steinberg GK, Mochly-Rosen D. DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo Brain Res 2007; 1144:146-155.
137. Sukamoto T, Shiono K, Watanabe TX, Sokabe H. Effects of beta-adrenergic blocking drugs in hypertensive rats. J Pharmacobiodyn 1980; 3:1-10.
138. Coyle P. Outcomes to middle cerebral artery occlusion in hypertensive and normotensive rats. Hypertension 1984; 6 (2 Pt 2): I69-74.
139. Dorrance AM, Rupp NC, Nogueira EF. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 2006; 47:590-595.
140. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008; 39:2824-2829.
141. Bath PMW, Gray LJ, Bath AJG, Buchan AM, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol 2009; 157:1157-1171.
142. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004; 35:1203-1208.
143. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 2005; 25:713-721.
144. van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 2007; 130 (Pt 12): 3063-3074.
145. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14.
146. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004; 27:1047-1053.
147. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. JAMA 1987; 257:949-952.
148. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13, 000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164:1422-1426.
149. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
150. Ray KK, Seshasai SRK, Wijesuriya S etal. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765-1772.
151. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M etal. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343:d4169.
152. Ottenbacher KJ, Ostir GV, Peek MK, Markides KS. Diabetes mellitus as a risk factor for stroke incidence and mortality in Mexican American older adults. J Gerontol A Biol Sci Med Sci 2004; 59:M640-645.
153. Megherbi SE, Milan C, Minier D etal. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 2003; 34:688-694.
154. Baird TA, Parsons MW, Phanh T etal. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003; 34:2208-2214.
155. Parsons MW, Barber PA, Desmond PM etal. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002; 52:20-28.
156. Gray CS, Hildreth AJ, Sandercock P etal. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6:397-406.
157. Liu L, Wang Z, Wang X etal. Comparison of two rat models of cerebral ischemia under hyperglycemic conditions. Microsurgery 2007; 27:258-262.
158. de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. Stroke 1989; 20:1707-1715.
159. Palmon SC, Sieber FE, Brown PR, Koehler RC, Eleff SM, Traystman RJ. Poor hemodynamic and metabolic recovery after global incomplete cerebral ischemia associated with short-term diabetes in dogs. J Cereb Blood Flow Metab 1995; 15:673-680.
160. Kraft SA, Larson CP Jr, Shuer LM, Steinberg GK, Benson GV, Pearl RG. Effect of hyperglycemia on neuronal changes in a rabbit model of focal cerebral ischemia. Stroke 1990; 21:447-450.
161. Morikawa S, Inubushi T, Ishii H, Nakasu Y. Effects of blood sugar level on rat transient focal brain ischemia consecutively observed by diffusion-weighted EPI and (1)H echo planar spectroscopic imaging. Magn Reson Med 1999; 42:895-902.
162. Kawai N, Keep RF, Betz AL, Nagao S. Hyperglycemia induces progressive changes in the cerebral microvasculature and blood-brain barrier transport during focal cerebral ischemia. Acta Neurochirurgica 1998; 71:219-221.
163. Martin A, Rojas S, Chamorro A, Falcon C, Bargallo N, Planas AM. Why does acute hyperglycemia worsen the outcome of transient focal cerebral ischemia? Role of corticosteroids, inflammation, and protein O-glycosylation. Stroke 2006; 37:1288-1295.
164. Ennis SR, Keep RF. Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab 2007; 27:1573-1582.
165. Li PA, Shuaib A, Miyashita H, He QP, Siesjo BK, Warner DS. Hyperglycemia enhances extracellular glutamate accumulation in rats subjected to forebrain ischemia. Stroke 2000; 31:183-192.
166. Gisselsson L, Smith ML, Siesjo BK. Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab 1999; 19:288-297.
167. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993; 24:111-116.
168. Wexler BC. Chronic diabetes followed by chronic cerebral ischemia induced by bilateral carotid artery ligation in arteriosclerotic versus nonarteriosclerotic rats. Stroke 1975; 6:432-434.
169. Huang NC, Wei J, Quast MJ. A comparison of the early development of ischemic brain damage in normoglycemic and hyperglycemic rats using magnetic resonance imaging. Exp Brain Res 1996; 109:33-42.
170. Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke 2007; 38:1044-1049.
171. Panes J, Kurose I, Rodriguez-Vaca D etal. Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation 1996; 93:161-167.
172. Toung TK, Hurn PD, Traystman RJ, Sieber FE. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000; 31:2701-2706.
173. Vannucci SJ, Willing LB, Goto S etal. Experimental stroke in the female diabetic, db/db, mouse. J Cereb Blood Flow Metab 2001; 21:52-60.
174. Li C, Li PA, He QP, Ouyang YB, Siesjo BK. Effects of streptozotocin-induced hyperglycemia on brain damage following transient ischemia. Neurobiol Dis 1998; 5:117-128.
175. Kittaka M, Wang L, Sun N etal. Brain capillary tissue plasminogen activator in a diabetes stroke model. Stroke 1996; 27:712-719.
176. Ergul A, Elgebaly MM, Middlemore ML etal. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol 2007; 7:33.
177. Moreira T, Cebers G, Pickering C, Ostenson CG, Efendic S, Liljequist S. Diabetic Goto-Kakizaki rats display pronounced hyperglycemia and longer-lasting cognitive impairments following ischemia induced by cortical compression. Neuroscience 2007; 144:1169-1185.
178. Ding C, He Q, Li PA. Diabetes increases expression of ICAM after a brief period of cerebral ischemia. J Neuroimmunol 2005; 161:61-67.
179. Ribo M, Molina CA, Delgado P etal. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cereb Blood Flow Metab 2007; 27:1616-1622.
180. Els T, Klisch J, Orszagh M etal. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis 2002; 13:89-94.
181. Guyot LL, Diaz FG, O'Regan MH, Song D, Phillis JW. The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglycemic ischemia. Brain Res 2000; 872:29-36.
182. Bomont L, MacKenzie ET. Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats. Neurosci Lett 1995; 197:53-56.
183. Wei J, Quast MJ. Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of reversible focal ischemia: detection of excitatory amino acids release and hydroxyl radical formation. Brain Res 1998; 791:146-156.
184. Coert BA, Anderson RE, Meyer FB. Effects of the nitric oxide donor 3-morpholinosydnonimine (SIN-1) in focal cerebral ischemia dependent on intracellular brain pH. J Neurosurg 2002; 97:914-921.
185. Coert BA, Anderson RE, Meyer FB. Is neuroprotective efficacy of nNOS inhibitor 7-NI dependent on ischemic intracellular pH? Am J Physiol 2003; 284:H151-159.
186. Kuroda S, Janelidze S, Siesjo BK. The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. Brain Res 1999; 835:148-153.
187. Toyonaga T, Kondo T, Miyamura N etal. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus. Diabetes Res Clin Pract 2002; 56:13-18.
188. Ericzon BG, Wijnen RM, Kubota K, Kootstra G, Groth CG. FK506-induced impairment of glucose metabolism in the primate - studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 1992; 54:615-620.
189. Sakakibara Y, Mitha AP, Ayoub IA, Ogilvy CS, Maynard KI. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res 2002; 931:68-73.
190. Slivka AP. Hypertension and hyperglycemia in experimental stroke. Brain Res 1991; 562:66-70.
191. Hamilton MG, Tranmer BI, Auer RN. Insulin reduction of cerebral infarction due to transient focal ischemia. J Neurosurg 1995; 82:262-268.
192. Zhang X, Patel A, Horibe H etal. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32:563-572.
193. Amarenco P, Labreuche J, Lavallee P, Touboul P-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-2909.
194. Amarenco P, Bogousslavsky J, Callahan A 3rd etal. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
195. Hayakawa K, Mishima K, Nozako M etal. High-cholesterol feeding aggravates cerebral infarction via decreasing the CB1 receptor. Neurosci Lett 2007; 414:183-187.
196. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32:980-986.
197. Laufs U, Gertz K, Huang P etal. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31:2442-2449.
198. Guo Q, Wang G, Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2010; 30:70-78.
199. Guo Q, Wang G, Liu X, Namura S. Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. Brain Res 2009; 1279:121-130.
200. Deplanque D, Gele P, Petrault O etal. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003; 23:6264-6271.
201. Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J Neurosci 2008; 28:4661-4670.
202. Famer D, Wahlund LO, Crisby M. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Biochem Biophys Res Commun 2010; 402:367-372.
203. Sawamura M, Nara Y, Yamori Y. Liver mevalonate 5-pyrophosphate decarboxylase is responsible for reduced serum cholesterol in stroke-prone spontaneously hypertensive rat. J Biol Chem 1992; 267:6051-6055.
204. Go AS, Hylek EM, Phillips KA etal. Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA 2001; 285:2370-2375.
205. Miyasaka Y, Barnes ME, Gersh BJ etal. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119-125.
206. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
207. Lin S, Wu B, Hao ZL etal. Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a Chinese hospital-based stroke study. Cerebrovasc Dis 2011; 31:419-426.
208. Marini C, De Santis F, Sacco S etal. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36:1115-1119.
209. Lip GY. The prothrombotic state in atrial fibrillation: the atrium, the endothelium ... And tissue factor? Thromb Res 2003; 111:133-135.
210. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298:789-794.
211. Weng W-C, Huang W-Y, Chien Y-Y etal. The impact of smoking on the severity of acute ischemic stroke. J Neurol Sci 2011; 308:94-97.
212. Iribarren C, Darbinian J, Klatsky AL, Friedman GD. Cohort study of exposure to environmental tobacco smoke and risk of first ischemic stroke and transient ischemic attack. Neuroepidemiology 2004; 23:38-44.
213. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43:1731-1737.
214. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96:1089-1096.
215. Ovbiagele B, Weir CJ, Saver JL, Muir KW, Lees KR. Effect of smoking status on outcome after acute ischemic stroke. Cerebrovasc Dis 2006; 21:260-265.
216. Myint PK, Welch AA, Bingham SA etal. Smoking predicts long-term mortality in stroke: the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study. Prev Med 2006; 42:128-131.
217. Raval AP, Bhatt A, Saul I. Chronic nicotine exposure inhibits 17beta-estradiol-mediated protection of the hippocampal CA1 region against cerebral ischemia in female rats. Neurosci Lett 2009; 458:65-69.
218. Raval AP, Hirsch N, Dave KR, Yavagal DR, Bramlett H, Saul I. Nicotine and estrogen synergistically exacerbate cerebral ischemic injury. Neuroscience 2011; 181:216-225.
219. Paulson JR, Yang T, Selvaraj PK etal. Nicotine exacerbates brain edema during in vitro and in vivo focal ischemic conditions. J Pharmacol Exp Ther 2010; 332:371-379.
220. Reynolds K, Lewis LB, Nolen JDL, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke. JAMA 2003; 289:579-588.
221. Mostofsky E, Burger MR, Schlaug G, Mukamal KJ, Rosamond WD, Mittleman MA. Alcohol and acute ischemic stroke onset. The Stroke Onset Study. Stroke 2010; 41:1845-1849.
222. Hillbom M. Alcohol consumption and stroke: benefits and risks. Alcohol Clin Exp Res 1998; 22 (7 Suppl.): 352S-358S.
223. Zakhari S. Alcohol and the cardiovascular system: molecular mechanisms for beneficial and harmful action. Alcohol Health Res World 1997; 21:21-29.
224. Altura BM, Gebrewold A, Altura BT, Gupta RK. Role of brain [Mg2+]i in alcohol-induced hemorrhagic stroke in a rat model: a 31P-NMR in vivo study. Alcohol 1995; 12:131-136.
225. Altura BM, Gebrewold A, Zhang A, Altura BT. Role of leukocytes in ethanol-induced microvascular injury in the rat brain in situ: potential role in alcohol brain pathology and stroke. Eur J Pharmacol 2002; 448:89-94.
226. Aronowski J, Strong R, Shirzadi A, Grotta JC. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 2003; 34:1246-1251.
227. Zhao X, Strong R, Piriyawat P, Palusinski R, Grotta JC, Aronowski J. Caffeinol at the receptor level: anti-ischemic effect of N-methyl-D-aspartate receptor blockade is potentiated by caffeine. Stroke 2010; 41:363-367.
228. Yoshimoto K, Komura S, Hattori H etal. Pharmacological studies of alcohol susceptibility and brain monoamine function in stroke-prone spontaneously hypertensive rats (SHRSP) and stroke-resistant spontaneously hypertensive rats (SHRSR). Tohoku J Exp Med 2003; 201:11-22.
229. Sacco RL, Boden-Albala B, Abel G etal. Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke 2001; 32:1725-1731.
230. Hajat C, Dundas R, Stewart JA etal. Cerebrovascular risk factors and stroke subtypes: differences between ethnic groups. Stroke 2001; 32:37-42.
231. Nakamura K, Barzi F, Lam TH etal. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region. Stroke 2008; 39:1694-1702.
232. Poulter NR, Chang CL, Farley TMM, Meirik O, Marmot MG. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348:498-505.
233. Higashiyama A, Wakabayashi I, Ono Y etal. Association with serum gamma-glutamyltransferase levels and alcohol consumption on stroke and coronary artery disease: the Suita study. Stroke 2011; 42:1764-1767.
234. Roquer J, Ois A, Rodriguez Campello A etal. Clustering of vascular risk factors and in-hospital death after acute ischemic stroke. J Neurol 2007; 254:1636-1641.
235. Rewell SS, Fernandez JA, Cox SF etal. Inducing stroke in aged, hypertensive, diabetic rats. J Cereb Blood Flow Metab 2010; 30:729-733.